In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy

Area of Science:

• Immunotherapy
• Cellular Therapy
• Biotechnology

Background:

• Chimeric antigen receptor-T (CAR-T) cell therapy is effective for hematological malignancies but faces challenges.
• Traditional CAR-T cell generation is complex, time-consuming, and expensive.
• In situ generation offers a potential solution to these limitations.

Purpose of the Study:

• To review the current advancements and future prospects of in situ-produced CAR-T cells.
• To explore alternative CAR-bearing immune effector cells like CAR-NK and CAR-macrophages.
• To highlight the potential benefits of in situ generation for reducing CAR-T therapy toxicities.

Main Methods:

• Review of preclinical studies and animal models.
• Analysis of viral and non-viral delivery systems for in situ CAR-T cell production.
• Evaluation of strategies for in situ generation of CAR-bearing immune effector cells.

Main Results:

• In situ CAR-T cell production can simplify the generation process.
• This approach holds promise for producing CAR-natural killer cells and CAR macrophages.
• In situ induction may mitigate common CAR-T toxicities like CRS and ICANS.

Conclusions:

• In situ CAR-T cell generation presents a promising translational strategy.
• Further preclinical and clinical validation is needed for practical medical application.
• This approach could expand the accessibility and safety of CAR-based immunotherapies.